Risk Factors and Center‐Level Variation in Hepatocellular Carcinoma Under‐Staging for Liver Transplantation

Nadim Mahmud, Maarouf A. Hoteit, David S. Goldberg – 4 May 2020 – Liver transplantation (LT) is curative for most patients with hepatocellular carcinoma (HCC). However, 10%‐15% of patients experience HCC recurrence. Patients who are reported as within Milan criteria by imaging are frequently found to be outside the criteria on explant. This under‐staging of HCC worsens post‐LT outcomes. However, risk factors for under‐staging have not been elucidated. Furthermore, it is not known if there is regional or center‐level variation in under‐staging.

Liver Transplantation for Acute‐on‐Chronic Liver Failure: Science or Fiction?

Jonel Trebicka, Vinay Sundaram, Richard Moreau, Rajiv Jalan, Vicente Arroyo – 4 May 2020 – Acute clinical deterioration of a patient with chronic liver disease remains a decisive time point both in terms of medical management and prognosis. This condition, also known as acute decompensation (AD), is an important event determining a crossroad in the trajectory of patients.

CLIF‐C Organ Failure Score and Liver Volume Predict Prognosis in Steroid‐Treated Severe Acute Autoimmune Hepatitis

Akihiko Ikura, Po‐sung Chu, Nobuhiro Nakamoto, Keisuke Ojiro, Nobuhito Taniki, Aya Yoshida, Masahiro Shinoda, Rei Morikawa, Karin Yamataka, Fumie Noguchi, Hitomi Hoshi, Shingo Usui, Hirotoshi Ebinuma, Yuko Kitagawa, Hidetsugu Saito, Takanori Kanai – 4 May 2020 – Controversies and debates remain regarding the best management of severe acute‐onset autoimmune hepatitis (SA‐AIH) due to the lack of useful outcome or complication prediction systems.

Longitudinal Association Between Markers of Liver Injury and Mortality in COVID‐19 in China

Fang Lei, Ye‐Mao Liu, Feng Zhou, Juan‐Juan Qin, Peng Zhang, Lihua Zhu, Xiao‐Jing Zhang, Jingjing Cai, Lijin Lin, Shan Ouyang, Xiaoming Wang, Chengzhang Yang, Xu Cheng, Weifang Liu, Haomiao Li, Jing Xie, Bin Wu, Huiming Luo, Fei Xiao, Jing Chen, Liang Tao, Gang Cheng, Zhi‐Gang She, Jianghua Zhou, Haitao Wang, Jun Lin, Pengcheng Luo, Shouzhi Fu, Jihui Zhou, Ping Ye, Bing Xiao, Weiming Mao, Liming Liu, Youqin Yan, Ling Liu, Guohua Chen, Hongliang Li, Xiaodong Huang, Bing‐Hong Zhang, Yufeng Yuan – 2 May 2020

Resection of Mixed Hepatocellular‐Cholangiocarcinoma, Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma

Matthew L. Holzner, Parissa Tabrizian, Fatemeh P. Parvin‐Nejad, Kezhen Fei, Ganesh Gunasekaran, Chiara Rocha, Marcelo E. Facciuto, Sander Florman, Myron E. Schwartz – 30 April 2020 – Mixed hepatocellular‐cholangiocarcinoma (HCC‐CC) is a biphenotypic liver cancer thought to have unfavorable tumor biology and a poor prognosis. Surgical outcomes of HCC‐CC remain unclear. We aimed to evaluate the clinical characteristics and surgical outcomes of HCC‐CC.

Subscribe to